Evidence map›Paper›PMID 39430801›Full record

ArticleJournal of diabetes research2024

Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study.

Gisle Langslet, Thomas Nyström, Dorte Vistisen, Bendix Carstensen, Emilie Toresson Grip, Paula Casajust, Giorgi Tskhvarashvili, Fabian Hoti, Riho Klement, Kristina Karlsdotter and 8 more

Abstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Gisle LangsletLipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital 0424, Oslo, Norway.
Thomas NyströmDepartment of Clinical Science and Education, Södersjukhuset, Karolinska Institutet 118 83, Stockholm, Sweden.
Dorte VistisenClinical Epidemiology, Steno Diabetes Center Copenhagen 2730, Herlev, Denmark.
Bendix CarstensenClinical Epidemiology, Steno Diabetes Center Copenhagen 2730, Herlev, Denmark.
Emilie Toresson GripReal World Data and Data Analytics, Quantify Research 11221, Stockholm, Sweden.
Paula CasajustReal-World Data and Data Analytics, TFS HealthScience 08007, Barcelona, Spain.ORCID https://orcid.org/0000-0003-2733-5436
Giorgi TskhvarashviliGlobal Database Studies, Real World Solutions, IQVIA 10119, Tallinn, Estonia.
Fabian HotiGlobal Database Studies, Real World Solutions, IQVIA 02130, Espoo, Finland.
Riho KlementGlobal Database Studies, Real World Solutions, IQVIA, 51013, Tartu, Estonia.
Kristina KarlsdotterMarket Access, Boehringer Ingelheim Pharmaceuticals 12032, Stockholm, Sweden.
Mikko TuovinenGlobal Medical Affairs, Boehringer Ingelheim Pharmaceuticals 00180, Helsinki, Finland.
Anne Pernille OfstadType 2 Diabetes and Metabolism, Medical Department, Boehringer Ingelheim 1383, Oslo, KS, Norway.
Maria LajerGlobal Integrated Evidence, Boehringer Ingelheim Pharmaceuticals 2100, Copenhagen, Denmark.
Christina ShayGlobal Integrated Evidence, Boehringer Ingelheim Pharmaceuticals, Inc. 06877, Ridgefield, Connecticut, USA.ORCID https://orcid.org/0000-0002-8310-7043
Lisette KoenemanDiabetes Global Medical Affairs, Lilly Deutschland GmbH 61352, Bad Homburg, Germany.
Soulmaz Fazeli FarsaniGlobal Integrated Evidence, Boehringer Ingelheim International GmbH 55216, Ingelheim, Germany.
Leo NiskanenPäijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital 15850, Lahti, Finland.
Sigrun HalvorsenDepartment of Cardiology, Oslo University Hospital Ullevål 0450, Oslo, Norway.ORCID https://orcid.org/0000-0001-7561-7644

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Benzhydryl CompoundsDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsGlucosidesHeart FailureHospitalizationKidney Failure, ChronicSodium-Glucose Transporter 2 InhibitorsAgedCohort StudiesFemaleHumansMaleMiddle AgedScandinavian and Nordic CountriesTreatment OutcomeBenzhydryl CompoundsDipeptidyl-Peptidase IV InhibitorsempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorscardiovascular diseasescomparative effectivenessdipeptidyl peptidase-4 inhibitorsempagliflozinend-stage renal diseaseheart failuresodium-glucose cotransporter-2 inhibitorstype 2 diabetes mellitus

Identifiers

PMID39430801
PMCPMC11490347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.